Trichy Daily

Diffuse cutaneous systemic sclerosis (dcSSc) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Diffuse cutaneous systemic sclerosis (dcSSc) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

August 01
08:53 2020
Diffuse cutaneous systemic sclerosis (dcSSc) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“Diffuse cutaneous systemic sclerosis (dcSSc) Market Insights, Epidemiology, and Market Forecast-2030”

 

(Albany, US) Delveinsight has launched a new report on “Diffuse cutaneous systemic sclerosis (dcSSc) – Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight’s Diffuse cutaneous systemic sclerosis (dcSSc) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Diffuse cutaneous systemic sclerosis (dcSSc) , historical and forecasted epidemiology as well as the Diffuse cutaneous systemic sclerosis (dcSSc) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the Key facts:

  • As per DelveInsight assessments, the market size of Diffuse cutaneous Systemic Sclerosis (dcSSc) in the 7MM was found to USD 228.60 million in 2017.
  • According to DelveInsight estimates, total prevalent population of Diffuse Cutaneous Systemic Sclerosis in 7MM was found to be 90,906 cases in 2017.
  • Among all the countries, The United States have higher population dcSSc with 38,584 cases in 2017
  • Among the EU5 countries, Italy has the highest prevalent cases with 10,863 cases, followed by the UK and France.
  • Germany had the lowest cases, whereas Japan had 13,384 cases of dcSSc in 2017

 

Scope of the Report:

  • The report covers the descriptive overview of Diffuse cutaneous systemic sclerosis (dcSSc) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Diffuse cutaneous systemic sclerosis (dcSSc) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Diffuse cutaneous systemic sclerosis (dcSSc) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Diffuse cutaneous systemic sclerosis (dcSSc) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Diffuse cutaneous systemic sclerosis (dcSSc) market

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/diffuse-cutaneous-systemic-sclerosis-dcssc-market

 

“As per DelveInsight’s analysts, women are found to be affected more with Diffuse Cutaneous Systemic Sclerosis than men. In 2017, there were 11,151 prevalent cases of dcSSc in men and 27,433 prevalent cases of dcSSc in women in the US.”

 

Diffuse cutaneous Systemic Sclerosis (dcSSc), a type of systemic sclerosis, is an autoimmune disease characterized by inflammation, vasculopathy, and fibrosis. The skin thickening is extended from proximal extremities from the elbows and knees to the abdomen or chest. Most common features in diffuse cutaneous systemic sclerosis includes cutaneous, renal, pulmonary, heart, and other organs involvement. Inflammation and subsequently fibrosis of internal organs such as lungs, heart, gastrointestinal tract, and kidneys results in decreased organ function and poor prognosis.

Scleroderma results from an overproduction and accumulation of collagen in body tissues. Genetic susceptibility plus a triggering event result in a cascade of innate and adaptive immunoinflammatory responses.

Environmental factors may also play a role such as exposure to silica, solvents, spirits, and certain medications that have an increased risk of developing systemic sclerosis. The usual initial symptom of Systemic Sclerosis is swelling, followed by thickening and tightening of the skin at the ends of the fingers. Heartburn, difficulty in swallowing, and shortness of breath are occasionally the first symptoms. Aches and pains in several joints often accompany early symptoms. Sometimes, inflammation of the muscles (myositis), with its accompanying muscle pain and weakness, develops. Raynaud’s phenomenon, often is the first sign of the disease, in which the fingers suddenly and temporarily become very pale and tingle or become numb, painful, or a combination of both in response to cold and sometimes emotional ups and downs may also showcase.

 

Key Companies:

  • Boehringer Ingelheim
  • Corbus Pharmaceuticals
  • Genentech, a member of the Roche group
  • GlaxoSmithKline
  • Beijing Continent Pharmaceutical/ Genentech
  • Bristol Myers Squibb
  • Kyowa Hakko Kirin
  • Viela Bio
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/diffuse-cutaneous-systemic-sclerosis-dcssc-market

 

Drugs Covered:

  • Nintedanib
  • Lenabasum
  • Tocilizumab
  • GSK 2330811
  • Belimumab
  • Pirfenidone
  • Abatacept
  • Brodalumab
  • Inebilizumab
  • VIB7734
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/diffuse-cutaneous-systemic-sclerosis-dcssc-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Diffuse cutaneous systemic sclerosis (dcSSc)

3. Competitive Intelligence Analysis for Diffuse cutaneous systemic sclerosis (dcSSc)

4. Diffuse cutaneous systemic sclerosis (dcSSc) : Market Overview at a Glance

4.1. Diffuse cutaneous systemic sclerosis (dcSSc) Total Market Share (%) Distribution in 2017

4.2. Diffuse cutaneous systemic sclerosis (dcSSc) Total Market Share (%) Distribution in 2030

5. Diffuse cutaneous systemic sclerosis (dcSSc) : Disease Background and Overview

6. Patient Journey

7. Diffuse cutaneous systemic sclerosis (dcSSc) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Diffuse cutaneous systemic sclerosis (dcSSc) Treatment

11. Marketed Products

12. Emerging Therapies

13. Diffuse cutaneous systemic sclerosis (dcSSc) : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Diffuse cutaneous systemic sclerosis (dcSSc)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/diffuse-cutaneous-systemic-sclerosis-dcssc-market

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market

Related Articles